Overall verdict
Neutral
4.5/10
1-year performance
+123.75%
Score breakdown
Up 123.8% over 1 year, 43% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 0.0/10.
5 analysts, target +1.6% vs the price.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET) ; KAT6A for the treatment of advanced breast cancer and other solid tumors ;
and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Krishna Vaddi
Founded
2016
Employees
79
Revenue / employee
153 671 USD
Next earnings
November 10, 2026 (estimated)
Institutional holders
- ORBIMED ADVISORS LLC17.20%
- BAKER BROS. ADVISORS LP12.69%
- RA CAPITAL MANAGEMENT, L.P.8.11%
- Soleus Capital Management, L.P.4.23%
- Kynam Capital Management, LP3.03%
- VANGUARD CAPITAL MANAGEMENT LLC2.52%
- BlackRock, Inc.2.25%
- SPHERA FUNDS MANAGEMENT LTD.1.28%
- TWO SIGMA INVESTMENTS, LP1.24%
- Other institutions9.60%
- Rest of the register37.85%
76 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
6.83 USD
52-week low
1.17 USD
1-year performance
123.75%
Rising
Year-to-date performance
23.45%
Rising
Drawdown
-47.58%
Major drawdown
Position in the 52-week range
43% of range
Gross margin 92.9%, the company loses 269.7% of its revenue, ROIC -50.5%, ROE -57.7%.
Net margin
-269.75%
Negative
Sector -223.73%|S&P 13.15%
Gross margin
92.92%
Exceptional
Return on equity (ROE)
-57.73%
Negative
Sector -58.98%|S&P 16.61%
Return on invested capital (ROIC)
-50.48%
Negative
Free cash flow margin (FCF)
-148.30%
Negative
Revenue to net income
Growth
10.0/10Revenue up 73.4% over 1 year.
Revenue (trailing 12 months)
22.4M USD
Revenue growth (1y)
73.43%
Hyper-growth
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector -0.03|S&P 0.90
Market cap
286M USD
Financial strength
10.0/10Cash covers 859.8% of the debt, no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-100.28%
Net cash
Cash
152M USD
Cash / market cap
53.12%
Very solid
Cash / total debt
859.81%
Net cash
Net debt
-134M USD
Equity
134M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 3.65 USD
- MM203.70
- MM504.72
- MM2003.96
- RSI 1441.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.51%
200-day average slope, 3 months
+30.92%
50-day average slope, 1 month
-5.90%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
3.64 % per day
Volatility change
-35.76%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.41 (5) | -0.57 (4) | 39 (5) | -66 (1) | -36 (4) |
| 2027 | -0.57 (4) | -0.58 (4) | 36 (4) | -97 (1) | -62 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 14, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.5 | 3.5 | 286M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | — | -11.6 % | 123.8 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | A376900 | 2.7 | 3.0 | 279M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.0 % | -46.6 % |
